HI
ICPT

HBK Investments’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

HBK Investments’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-15,478
Closed -$2.31M – 1156
2015
Q4 		$2.31M Buy
+15,478
New +$2.62M 0.02% 380
2014
Q4 		– Sell
-8,500
Closed -$2.01M – 1167
2014
Q3 		$2.01M Sell
8,500
-19,600
-70% -$5M 0.03% 383
2014
Q2 		$6.65M Buy
28,100
+13,800
+97% +$3.64M 0.14% 142
2014
Q1 		$4.72M Buy
+14,300
New +$4.83M 0.09% 176

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HBK Investments's ICPT Position: Q1 2016 in Review

HBK Investments sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2016, closing a stake of 15,478 shares — an estimated $2.31M sold.

HBK Investments first reported a position in ICPT in Q1 2014 and held it in 4 quarters. The position peaked at $6.65M in Q2 2014. 160 funds tracked by Wall St. Rank hold ICPT as of Q1 2016.

  • HBK Investments reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • HBK Investments sold 15,478 Intercept Pharmaceuticals, Inc. shares in Q1 2016, an estimated $2.31M.
  • HBK Investments first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 4 quarters.
  • HBK Investments's Intercept Pharmaceuticals, Inc. position peaked at $6.65M in Q2 2014.
  • 160 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2016.

Based on HBK Investments's 13F filing for Q1 2016, filed 13 May 2016.